Clinical Trials Browser

Phase 2 × Muscle Invasive Bladder Urothelial Carcinoma × pembrolizumab × Clear all

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma